NCT02102646

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 31 (actual)
• Sponsor: Herlev Hospital · Academic / Other
• Sex: Male
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.

Detailed description

This is a substudy of the ongoing randomized trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 2013-002553-29). 20 consecutive patients are anticipated to participate regardless of assignment to either orchiectomy or triptorelin.

Conditions

• Prostate Cancer
• Metabolic Syndrome
• Hypogonadism
• Fatty Liver

Interventions

Type	Name	Description
DRUG	Triptorelin	Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
PROCEDURE	Orchiectomy	Androgen deprivation therapy by bilateral subcapsular orchiectomy

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-04-03
• Last updated: 2015-10-28

Locations

1 site across 1 country: Denmark